- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 277/593 - Z being doubly bound oxygen or doubly bound nitrogen, which nitrogen is part of a possibly substituted oximino radical
Patent holdings for IPC class C07D 277/593
Total number of patents in this class: 23
10-year publication summary
|
1
|
4
|
2
|
1
|
2
|
2
|
1
|
0
|
2
|
0
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Arizona Board of Regents on behalf of Arizona State University | 2934 |
4 |
| Vivakor, Inc | 91 |
4 |
| The Medical College of Wisconsin, Inc. | 456 |
2 |
| Theravance Biopharma Antibiotics IP, LLC | 5 |
2 |
| Translational Drug Development, LLC | 35 |
2 |
| The Board of Regents of the University of Texas System | 2296 |
2 |
| Concortis Biosystems, Corp | 5 |
2 |
| Bristol-myers Squibb Company | 4742 |
1 |
| Hoffmann-La Roche Inc. | 3793 |
1 |
| BioMarin Pharmaceutical Inc. | 400 |
1 |
| Bionevia Pharmaceuticals, Inc. | 12 |
1 |
| Desai, Laxman S. | 3 |
1 |
| Other owners | 0 |